Trial Profile
Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Paediatric Subjects With Congenital Fibrinogen Deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fibrinogen (Primary)
- Indications Afibrinogenaemia
- Focus Registrational; Therapeutic Use
- Acronyms FORMA04
- Sponsors Octapharma
- 29 Mar 2021 According to a Food and Drug Administration media release, for fibryga (human fibrinogen concentrate), the FDA approved Octapharmas request to expand the indication for on-demand treatment of acute bleeding episodes to pediatric patients less than 12 years old with congenital fibrinogen deficiency (CFD), also known as Factor 1 deficiency. The expansion was supported by the results of this Phase 3 study.
- 29 Mar 2021 According to a Food and Drug Administration media release, results from the FORMA-02 and FORMA-04 clinical trials will be presented at the virtual American Society of Pediatric Hematology/Oncology (ASPHO) 2021.
- 08 Dec 2020 Results assessing efficacy and safety of HFC for the treatment of bleeding episodes (BEs) and surgical prophylaxis in adult, adolescent and pediatric patients from two studies (FORMA-02 and FORMA-04 ), presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.